NEW YORK, June 6, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition <\/p>\n
http:\/\/www.reportlinker.com\/p0203691\/Outsourcing-in-Drug-Discovery-The-Contract-Research-Organization-CRO-Market-5th-Edition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development<\/a> <\/p>\n The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA). <\/p>\n Since the last edition of Kalorama's Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market. <\/p>\n Segments covered in this report with market size estimates include: <\/p>\n In addition to market data and forecasts, the report covers issues such as: <\/p>\n This report provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. <\/p>\n The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives. <\/p>\n CHAPTER ONE: EXECUTIVE SUMMARY <\/p>\n<\/p>\n View original post here: NEW YORK, June 6, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition http:\/\/www.reportlinker.com\/p0203691\/Outsourcing-in-Drug-Discovery-The-Contract-Research-Organization-CRO-Market-5th-Edition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development<\/a> The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. Continue reading
\nOutsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"